Introduction {#s001}
============

N[eutralizing antibodies were]{.smallcaps} among the first inhibitors identified against human immunodeficiency virus type 1 (HIV-1) infections. Active immunization to generate an appropriate *de novo* HIV neutralizing antibody response remains the ultimate goal but has proved challenging.^[@B1]^ Passive topical delivery of antiviral antibodies at or on mucosal surfaces, in the vaginal and cervix, can interrupt the cycle of virus infection^[@B2]^; however, obtaining and maintaining effective levels of such antiviral antibodies can be costly and short lived.

Thus, new strategies are needed for providing neutralizing antibodies at the mucus surface where HIV is transmitted. One innovative avenue is to use a recombinant commensal *Lactobacillus* as a vehicle for releasing neutralizing antibodies at the mucosa. *Lactobacillus* species are common members of the vaginal microbiota in healthy women of childbearing age^[@B7],[@B8]^ and interact with the host to reduce proinflammatory cytokine levels and serve as the major host inflammatory modulator.^[@B9]^ *Lactobacillus jensenii* is one of the more predominant vaginal lactobacilli. The strain *L. jensenii* 1153 has been proven as a potential platform to deliver sufficient levels of the anti-HIV protein-modified cyanovirin-N to mucosal surfaces to protect macaques from Simian (S)HIV challenge.^[@B10]^

HIV-1 entry into target cells requires the sequential binding of the viral envelope glycoprotein gp120 epitopes to CD4 and then to the CCR5 chemokine receptor.^[@B11]^ When CD4 binds to the HIV envelope, a conformation change in gp120 exposes the cryptic epitopes known as the CD4-induced (CD4i) site.^[@B12],[@B13]^ When a CD4i antibody is present, it recognizes these previously unexposed sites, blocking virus attachment of HIV to the chemokine receptor.^[@B14]^

Different variants of anti-HIV antibodies have been developed, such as single-chain variable fragments (scFvs), small antibody fragments, and even smaller domain antibodies (dAbs). These alternatives offer advantages over conventional antibodies because of their smaller size, robustness, and their ability to be expressed in bacteria. Moreover, the small size of the dAbs and scFvs overcomes the steric constraints when the virion is bound to CD4; an intact IgG molecule may not be able to access the CD4i bridging sheet.^[@B15]^ Numerous scFvs and dAb variants and camel-derived antibodies have now been identified that retain the broadly neutralizing anti-HIV activity.^[@B16]^ Among these broadly neutralizing antibody fragments are ScFv-m9,^[@B23],[@B24]^ dAb-m36,^[@B25],[@B26]^ and dAb-36.4 variant^[@B19]^ that bind CD4i regions and facilitate neutralization of a broad range of HIV isolates.

We selected these antibody fragments that target the highly conserved CD4i epitopes, for expression in *Lactobacillus* as entry inhibitors, since they are likely to be present across the wide genetic diversity of HIV-1 variants. In addition, their small size may put less strain on the recombinant *Lactobacillus* allowing for expression levels that are biologically relevant.

In this article, we optimized and compared the expression of scFV-m9, dAb-m36, and dAb-m36.4 by *L. jensenii*. We evaluated the breadth and potency of dAb-m36.4 against different HIV-1 subtypes. Finally, we constructed a recombinant *L. jensenii* 1153-1128 producing dAb AP-m36.4.

Materials and Methods {#s002}
=====================

Bacterial strains, culture, plasmid construction, and transformation {#s003}
--------------------------------------------------------------------

*L. jensenii* strain 1153, a vaginal isolate from a healthy woman, was cultivated as described previously.^[@B27]^ To express m9 or m36 antibody fragments in *L. jensenii* 1153, the *m9* or *m36* genes were cloned into the modular shuttle vector pOSEL175, a modified version of pOSEL144.^[@B27]^ The expression cassette for secreted scFv-m9 or dAb-m36 contained the *Lactococcus* promoter p23, the signal sequence from the ribosome binding site to the signal peptidase cleavage site of the *L. crispatus* S-layer gene (*CbsAss*) (for protein secretion), and a C-terminal epitope tag DYKDDDDK (FLAG) with a TAA stop codon at the 3′ end.

For purification ease, Profectus Biosciences Inc. modified the cassettes for the *m9*, *m36*, and *m36.4* genes to include a C-terminal albumin-binding domain (ABD), SA06 for improving its pharmacokinetic properties and also aiding in purification using rat serum albumin (RSA) columns.^[@B28]^ The original *m9* and *m36* genes do not bind albumin. The OSEL shuttle plasmids were maintained and propagated in *Escherichia coli*, purified, and electroporated into *L. jensenii* 1153 as described before,^[@B27]^ generating the transformed strains *L. jensenii* 1153-1126p (expressing m9), *L. jensenii* 1153-1127p (expressing m36), and *L. jensenii* 1153-1128p (expressing m36.4). Transformed lactobacilli were routinely propagated using Man Rogosa Sharpe (MRS) or Rogosa media (broth or agar) with 20 μg/ml of erythromycin. *L. jensenii* 1153-1128 was propagated on MRS or Rogosa broth or agar without antibiotic.

Western blots {#s004}
-------------

Stationary-phase supernatants from transformed (plasmid expressed) *L. jensenii* 1153-1126p, *L. jensenii* 1153-1127p, and *L. jensenii* 1153-1128p were harvested and centrifuged to remove cell debris. Thirty microliters of supernatant was run on a 12% Bis-Tris Gel (Life Technologies) and transferred to polyvinylidene difluoride membranes using an iBlot (Life Technologies). The m9, m36, or AP-m36.4 proteins were detected using monoclonal mouse anti-FLAG antibody (Pierce Thermo) dilutes 1:1,000 and the anti-mouse Western Breeze Chemiluminescent Kit (Life Technologies).

Purification and bioactivity characterizations of *Lactobacillus*-derived m36.4 {#s005}
-------------------------------------------------------------------------------

The *L. jensenii* strains expressing m9 and m36 (each containing the ABD) from plasmids were cultured in Rogosa SL broth (Difco) to stationary phase. Cell-free supernatants were centrifuged, filtered, and purified using the (i) albumin Sepharose column (RSA bound to cyanogen bromide \[CNBr\]-activated Sepharose 4B; GE Healthcare) or (ii) full-length single-chain (FLSC) column (gp120/CD4 complex bound to CNBr-activated Sepharose 4B). In both methods, the columns were equilibrated with phosphate-buffered saline (PBS), the supernatant supplemented with 0.5 M sodium chloride (NaCl) passed slowly through the column to ensure at least 1 min of contact time, column washed with at least 20 bed volumes PBS supplemented with 0.5 M NaCl and m36 eluted with 0.2 N citric acid, pH 3.0.

The eluant was immediately neutralized to pH 6.0--8.0 using 1 M Tris at pH 9.0 and dialyzed against PBS. Control *E. coli* expressed m36.4 was purified by sequential ion exchange column (Q HP Sepharose Fast Flow columns; GE Healthcare Life Sciences) and size exclusion column (Superdex 75 column, 120 ml bed volume; GE Healthcare). Periplasmic extract from HB2151 expressing m36.4 was dialyzed against 20 mM piperazine, pH 5.8, centrifuged at 14,000 *g* for 30 min, and loaded onto the Q HP column. The column was washed with 20 mM piperazine, 0.15 M NaCl, pH 5.8 buffer, and the bound protein eluted using gradient salt elution from 0.15 to 0.50 M NaCl. M36 and m36.4 eluted in the peak in the range of 0.2 M NaCl. The collected eluant from this peak was passed through a size exclusion column to eliminate the majority of high-molecular weight contaminants.

Preparations of m9, m36, and m36.4 were quantified by Coomassie blue staining and gp120/CD4 capture enzyme-linked immunosorbent assay (ELISA). FLSC (CD4-gp120) leached from column was removed by an additional passage over an RSA column. The amount of RSA leached from the column was insignificant.

Although LPS levels were not measured following purification from *E. coli*, similar antibody fragments purified previously had \<10 EU/mg of protein.

Gp120/CD4 binding (capture ELISA) {#s006}
---------------------------------

A sheep antibody, D7324 (Aalto Bio Reagents), which binds to a motif (amino acid 497--511) in the envelope gene gp120, was coated on ELISA plates at 2°C--8°C, at a concentration of 2 μg/ml, overnight. Plates were then washed with Tris-buffered saline with Tween (TBST) and blocked with 5% skim milk. FLSC (a gp120/CD4 complex), at a concentration of 0.2 μg/ml in PBS, was captured on D7324 and the plate was washed with TBST. Titrated samples of m9, m36, and m36.4 solution were overlaid onto the FLSC, incubated for 1 h, and washed with TBST. All antibody fragments bound to FLSC and were detected using the horseradish peroxidase (HRP)-conjugated mouse anti-FLAG antibody (clone M2; Sigma).

Peripheral blood mononuclear cell neutralization assay (p24 assay) {#s007}
------------------------------------------------------------------

Human peripheral blood mononuclear cells (PBMCs) were purchased from SeraCare Life Sciences, Inc. HIV-1~BaL~ virus was initially received from the NIH AIDS Reagents Program and later grown by Profectus Biosciences for laboratory use. PBMCs were infected with HIV-1~BaL~ at a multiplicity of infection of 0.01 in the presence of m36.4 (purified as described above) with desired concentrations. The mixture was incubated at 37°C for 1 week, and the supernatant was lysed using 1% Triton X-100 and quantified for p24 presence by using a p24 capture ELISA developed at Profectus BioSciences, Inc. Plates were coated with 3 μg/ml mouse monoclonal anti-p24 antibody (clone 39/6.14 by ZeptoMetrix) washed with TBST, blocked with 5% casein and 4% rabbit serum, washed with TBST, overlaid with the lysed p24 containing supernatant, incubated for 1 h, and washed with TBST. Bound p24 was detected using the HRP-conjugated rabbit polyclonal anti-p24 antibody (1303-P; ImmunoDX, LLC).

Construction of recombinant *L. jensenii* 1153-1128 {#s008}
---------------------------------------------------

Before insertion of the antibody cassette into the *Lactobacillus* chromosome, two modifications were made. The two-amino-acid peptide (AP), corresponding to the N terminus of the mature CbsA protein, was inserted downstream of the CbsA signal sequence at the N-terminus of the m36 protein to more closely resemble the native signal peptidase cleavage site of this protein. A point mutation at amino acid 44 glutamine (Q) to glutamic acid (E) Q44E was substituted for the original sequence.^[@B19]^ This point mutation, also called m36.4, confers greater breadth against HIV-1. The *AP-m36.4* gene was cloned into Osel\'s integration vector.

For stable expression of AP-m36.4 in *Lactobacillus*, the *AP-m36.4* gene expression cassette was integrated in single copy into the *L. jensenii* 1153 genome by homologous recombination into the *minor capsid* gene. The recombinant strain was selected by replicate plating into MRS agar with and without erythromycin. During successful integration, resolution of the plasmid occurs, which removes the erythromycin resistance gene. The integrated and resolved strain *L. jensenii* 1153-1128 contains a single copy of *AP-m36.4* gene and requires no antibiotic selection. The recombinant strain *L. jensenii* 1153-1128 was maintained in the MRS broth.

TZM-bl neutralization assay {#s009}
---------------------------

The TZM-bl neutralization assay was used to evaluate antibody breadth and potency of m36.4.^[@B29]^ Neutralization experiments are expressed as IC~50~ titer of the protein in μg/ml. m9 and m36 were not tested.

Results {#s010}
=======

Expression of antibody fragments in *L. jensenii* {#s011}
-------------------------------------------------

We tested the feasibility of expressing anti-HIV-1 antibody fragments using a human vaginal *Lactobacillus* expression platform to produce a recombinant live biotherapeutic against HIV-1. We examined the scFv-m9^23,24^ and single dAb-m36 (CD4i epitope)^[@B25],[@B26]^ and its derivative m36.4.^[@B19]^ We cloned the *m9* and *m36* genes, which contained an ABD for purification^[@B28]^ and FLAG tag (for easy detection) into Osel\'s *Lactobacillus* expression vector p175 under the p23 promoter and transformed *L. jensenii* 1153. A diagram of the plasmid construction of pOSELp23-*m9* and pOSELp23-*m36* is shown ([Fig. 1A](#f1){ref-type="fig"}). Supernatants from *L. jensenii* secreting m9 or m36 are detected by using an anti-Flag antibody and compared with a purified protein standard produced in *E. coli* ([Fig. 1B](#f1){ref-type="fig"}). The estimated concentrations of m9 and m36 secreted were ∼660 and 4.0 μg/ml, respectively.

![Plasmids used in this study and protein expression. **(A)** Expression plasmids for scFv-*m9* and dAb-*m36* are shown. Plasmids contain promoter P23 (*green*), Lcss (*red*), antibody fragment (*blue*), ABD (*pink*), and Flag epitope (*orange*). **(B)** Proteins and standards were run on 12%-Bis-Tris gels, transferred to PVDF membrane, and visualized with anti-FLAG antisera. *Lane 1,* m9 standard 20 ng, *Lane 2, Lactobacillus jensenii* expressed m9 (30 μl loaded), *Lane 3,* m36 standard 20 ng, *Lane 4,* m36 standard 10 ng, *Lane 5, L. jensenii* expressed m36 (10 μl loaded). ABD, albumin-binding domain; dAb, domain antibody; Lcss, *L. crispatus* signal sequence; PVDF, polyvinylidene difluoride; scFv, single-chain variable fragment.](fig-1){#f1}

Binding of antibody fragments to FLSC {#s012}
-------------------------------------

Supernatants of scFv-m9 and m36 expressed from plasmids transformed into *L. jensenii* 1153 were purified and tested for functionality by determining binding to FLSC ([Fig. 2A, B](#f2){ref-type="fig"}). The scFv-m9 plasmid expressed by *L. jensenii* or scFv-m9 expressed by *E. coli* bound to the gp120-CD4 complex in ELISA, while the control supernatant from *L. jensenii* did not (data not shown); however, scFv-m9 expressed by *L. jensenii* bound with lower affinity ([Fig. 2A](#f2){ref-type="fig"}). Due to lower expression levels and lower affinity, scFv-m9 was not pursued further.

![ELISA readout of binding of antibody fragments to FLSC (gp120/CD4) and purity of m36.4 and AP-m36.4. Comparison of binding properties from antibody fragments produced by *L. jensenii* (*blue*) to *Escherichia coli* produced standards (*red*). **(A)** scFv-m9; produced from plasmid **(B)** dAb-m36; produced from plasmid **(C)** dAb-m36.4 (*E. coli*) versus dAb-AP-m36.4 (recombinant *L. jensenii* 1153-1128). Alanine proline N-terminal m36.4 (AP-m36.4). ELISA, enzyme-linked immunosorbent assay; FLSC, full-length single chain.](fig-2){#f2}

*L. jensenii* plasmid-expressed m36 bound to FLSC to the same level as the standard ([Fig. 2B](#f2){ref-type="fig"}). The recombinant *L. jensenii* 1153-1128 expressed a modified version of m36.4, with the addition of amino acids alanine (A) and proline (P) at the amino terminus. Addition of the AP-sequence was previously shown to improve the secretion of full-length protein from *L. jensenii*.^[@B30]^ Both *E. coli*-expressed m36.4 and recombinant *L. jensenii* 1153-1128-expressed AP-m36.4 were tested to confirm that the addition of AP to the amino terminus of m36.4 did not influence binding to FLSC ([Fig. 2C](#f2){ref-type="fig"}). The EC~50~s were comparable: *E. coli* produced dAb-m36.4 12.7 ng/ml and recombinant *L. jensenii* 1153-1128 produced AP-m36.4 11.9 ng/ml (no statistical difference).

Antiviral activity of m36.4 {#s013}
---------------------------

*L. jensenii-*expressed m36.4 was purified using two techniques; purity of the protein using the different strategies is shown in [Figure 3A](#f3){ref-type="fig"}. Purified m36.4 was tested for anti-HIV activity using a p24-PBMC-based assay ([Fig. 3B](#f3){ref-type="fig"}). Both RSA-purified m36.4 and FLSC-purified m36.4 showed similar reduction of p24, and thus, the *Lactobacillus*-produced m36.4 protein was active against HIV~BaL~ with an IC~50~ of ∼1 μg/ml.

![Purification of AP-m36.4 protein used for HIV inhibition assay. **(A)** *Lane 1:* see Blue Plus Prestained ladder (Invitrogen), *Lane 2:* m36.4 *E. coli*, 3 μg (purified on Q, HP, size-exclusion columns), *Lane 3: L. jensenii* 1153-1128 expressed AP-m36.4, 3 μg (purified on RSA column), *Lane 4: L. jensenii* 1153-1128 expressed AP-m36.4, 7.4 μg total protein (purified on FLSC *column*) \* FLSC (CD4-gp120) leached from column was removed by RSA. **(B)** AP-m36 produced by recombinant *L. jensenii* 1153-1128 inhibits HIV~BaL~. Bar graph showing the p24 value measured. Each value is average of four replicates. IC~50~ for AP-m36.4 produced in *Lactobacillus* is ∼1 μg/ml. RSA, rat serum albumin.](fig-3){#f3}

Neutralization breadth of m36.4 {#s014}
-------------------------------

[Table 1](#T1){ref-type="table"} details the breadth of neutralization of the m36.4 protein. m36.4 was purified from *E. coli* and tested for activity against a panel of 68 pseudoviruses from each of the major genetic subtypes representing clades A, B, C, D, G, including transmitted founders (T/F) and circulating recombinant forms CRF01 AE and CRF02 AG. [Table 1](#T1){ref-type="table"} shows the broadly neutralizing activity of m36.4 against clades B, C, and D; most IC~50~ values were in the ≤5 μg/ml. Less or no activity was noted against clades A, G, and CRFs. Previously, we tested a partially purified supernatant from wild-type *L. jensenii* in pseudovirus assays with HIV-1~HxB2~ envelope and found no inhibition.^[@B27]^ In addition, m36.4 did not inhibit MuLV control in the TZM-bl assay.

###### 

[IC~50~ Titer m36.4 in TZM-bl Cells (]{.smallcaps}μ[g/ml)]{.smallcaps}

  -------------------- ------- -------------- ------- ----------------- -------
  A                    BC      CRF01-AE                                 
   Q461.e2             3.433    CNE19         0.446    620345.c01       \>20
   Q769.d22            2.759    CNE20         0.757    R2184.c04        \>20
   Q23.17              6.507    CNE17         1.357    R1166.c01        \>20
   Q259.d2.17          11.80    CNE30         6.113    R3265.c06        \>20
   0330.v4.c3          8.322    CNE52         0.508    C3347.c11        \>20
   0260.v5.c36         19.80    CNE53         3.008    C4118.c09        \>20
  AC                           C                       CNE5             \>20
   3301.v1.c24         1.464    Du156.12      3.729   CRF01-AG           
   6041.v3.c23         3.521    Du172.17      1.926    T250-4           0.694
   6540.v4.c1          \>20     Du422.1       2.904    T255-34          0.814
  ACD                           ZM197M.PB7    0.937    T257-31          11.71
   0815.v3.c3          0.492    ZM233M.PB6    10.77    928-28           16.68
   3103.v3.c10         2.763    ZM249M.PL1    0.210    263-8            8.705
  B                             ZM53M.PB12    0.286    T251-18          \>20
   6535.3              0.949    ZM214M.PL15   1.876    T278-50          11.46
   QH0692.42           0.965   C (T/F)                D                  
   SC422661.8          1.400    Ce0393_C3     0.262    3016.v5.c45      0.377
   PVO.4               0.810    Ce1176_A3     2.650    A07412M1.vrc12   0.953
   TRO.11              3.666    Ce2010_F5     3.621    231965.c01       3.720
   AC10.029            1.260    BF1266.431a   0.256   D (T/F)            
   RHPA4259.7          3.885   CD                      191821_E6_1      0.194
   THRO4156.18         2.059    3817.v2.c59   3.484   G                  
  B (T/C)                       6952.v1.c20   0.734    X1193_c1         \>20
   WEAU_d15_410_5017   3.584    89-F1_2\_25   0.134    P0402_c2_11      \>20
   1006_11_C3_1601     0.885    6811.v7.c18   \>20     X1254_c3         \>20
   1054_07_TC4_1499    1.894                           X2088_c9         \>20
                                                       X2131_C1_B5      \>20
                                                       P1981_C5_3       18.45
  -------------------- ------- -------------- ------- ----------------- -------

T/F, transmitted founders.

Construct integration vectors and integrated single domain expression cassettes into the *L. jensenii* 1153 chromosome and tested phenotypic stability {#s015}
------------------------------------------------------------------------------------------------------------------------------------------------------

We constructed a recombinant *L. jensenii* 1153 by integrating an optimized AP-m36.4 antibody expression cassette into the *minor capsid* gene of *L. jensenii* 1153 through homologous recombination ([Fig. 4A](#f4){ref-type="fig"}). The strains generated were evaluated for complete resolution of the plasmid and antibody production (not shown). A diagram of the two sets of internal and external primers, which were used to amplify the integration region within the *minor capsid* gene, is shown ([Fig. 4B](#f4){ref-type="fig"}).

![Construction and characterization of recombinant *Lactobacillus*. **(A)** Construction of *L. jensenii* 1153-1128 was performed by site-specific integration of the p23-*AP-m36.4* gene into the *minor capsid* gene locus in the *Lactobacillus* chromosome. A diagram of the recombinant construction is shown. **(B)** PCR fragment length analysis of the parent and recombinants. PCR was carried out using primers within the *minor capsid* gene and flanking the AP-m36.4 expression cassette 891 bp Int, and with primers external to the *minor capsid* gene. The parental strain shows a 353 bp fragment when amplified by internal primers and a 1,824 bp fragment when amplified by the Ext primers. Recombinant strain WCB 1128 shows a 1,250 and 2,721 bp fragment, respectively, with the insertion of the 891 cassette plus a 6 bp restriction site. A long-term (40 generation) culture also showed the same PCR fragment length pattern. **(C)** Growth curves are shown for the parental *L. jensenii* 1153 strain and recombinant *L. jensenii* 1153-1128 strain, under anaerobic and 5% CO~2~ growth conditions. **(D)** Lactic acid production as measured by pH is shown for the parental *L. jensenii* 1153 strain and recombinant *L. jensenii* 1153-1128 strain, under anaerobic and 5% CO~2~ growth conditions. Ext, external; Int, integration site; PCR, polymerase chain reaction; WCB, working cell bank.](fig-4){#f4}

Polymerase chain reaction (PCR)-amplified genomic DNA from the parental *L. jensenii* 1153 and recombinant strain designated *L. jensenii* 1153-1128 were run on a 2% agarose gel. *L. jensenii* 1153 shows a 353 bp band corresponding to a region of the *minor capsid* gene and a 1,824 bp band of the entire *minor capsid* gene ([Fig. 4B](#f4){ref-type="fig"}). *L. jensenii* 1153-1128 shows a 1,250 bp band corresponding to a region of the *minor capsid* gene with the 891 bp band (+6 bp restriction site) cassette insertion. The external primers amplify a 2,721 bp band (1,824 + 891 + 6 bp).

The strain was passaged 40 generations, genomic DNA was extracted, and the cassette was sequenced (not shown). The 40-generation sample was also analyzed by PCR for stability. No changes were noted in the size of the internal and external primer bands 891 and 2,721, respectively, and thus, the *L. jensenii* 1153-1128 recombinant is genotypically stable. We examined phenotypic stability by performing a carbohydrate utilization profile of parental strain *L. jensenii* 1153. Both *L. jensenii* 1153 and *L. jensenii* 1153-1128 fermented glucose, [d]{.smallcaps}-fructose, [d]{.smallcaps}-mannose, *N*-acetylglucosamine, amygdalin, arbutin, wells, salicin, [d]{.smallcaps}-cellobiose, [d]{.smallcaps}-maltose, [d]{.smallcaps}-saccharose, amidon (starch), and gentiobiose wells and hydrolyze esculin ferric citrate (data not show).

We tested growth of the 1153-1128 strain and lactic acid production (pH) and compared them to parental strain *L. jensenii* 1153. *L. jensenii* 1153-1128 grew to the same level as the parental strain and reduced pH of the media under aerobic (5% CO~2~) and anaerobic growth conditions ([Fig. 4C, D](#f4){ref-type="fig"}).

Discussion {#s016}
==========

There is a tremendous need for approaches to combat HIV-1 transmission in women of reproductive age. Lactobacilli (including *L. jensenii*) are important members of the vaginal microbiome, lowering vaginal pH,^[@B31],[@B32]^ modulating cervicovaginal inflammation,^[@B9]^ and providing resistance to HIV infection.^[@B33]^ We established the feasibility of expressing bioactive anti-HIV-1 antibody fragments from a vaginal strain of *L. jensenii* and show that these fragments are functional and can be stably expressed from a recombinant *L. jensenii*. In addition, we confirmed that the recombinant *L. jensenii* 1153-1128 expressing m36.4 could colonize the rhesus macaque vagina (data not shown).

ScFv-m9 was expressed at lower levels and had lower affinity for FLSC, so it was not pursued. However, the smaller dAbs m36 and m36.4 could be expressed at high levels and thus were more viable for this approach. It is noteworthy to mention that the small dAb fragments m36 and m36.4 can bind the CD4i epitope even without the conformational change that occurs with CD4 binding to gp120.

Previously, several groups have used other commensals to express functional antibody fragments. Early work used the commensal *Streptococcus gordonii* engineered to produce scFv H6 and an anti-idiotypic scFv with anti-*Candida* activity.^[@B34],[@B35]^ *S. gordonii* was also used to produce Guy\'s 13 scFv against the caries-producing bacterium *Streptococcus mutans*.^[@B36]^

Marcotte *et al.* expressed scFv on the surface of *Lactobacillus paracasei* against *Porphyromonas gingivalis*,^[@B37]^ and Kruger *et al.* used *Lactobacillus casei* expressing an scFv against *S. mutans*,^[@B38]^ both approaches reduced dental caries. *L. paracasei* was used to express an scFv to protect against anthrax edema toxin caused by the bacterium *Bacillus anthracis*.^[@B39]^ *L. casei*, *L. paracasei*, and *Lactobacillus rhamnosus* GG were engineered to express llama VHH antibody fragments against rotavirus.^[@B40],[@B41]^ Most recently, Andersen *et al.* described the use of single dAbs to neutralize *Clostridium difficile* toxin B.^[@B42]^

Another noteworthy approach is the use of adeno-associated virus (AAV) to deliver broadly neutralizing antibodies.^[@B43]^ While the approach appears to be safe, and the AAV are long lived in the tissue and can secrete antibody persistently, one caveat with this approach is the inability to remove the AAV vector easily, should the need arise. Commensal bacteria (expressing antibodies) can be removed by treatment with an appropriate antibiotic.

Although the idea of expressing antibody fragments in commensals is not new, with the increasing development of antibiotic and antiviral resistance and therefore fewer treatment options for both bacterial and viral infections, new approaches are needed. With a better appreciation of the health benefits provided by commensals as part of the microbiome, perhaps this is an approach whose time has come.

For prevention of HIV, the benefit to using human colonizing vaginal strains would allow for delivery of antibodies mucosally at the site where the virus first enters the body. Development of broadly neutralizing antibodies in infected individuals, in the blood or at mucosal sites, takes months to years. Current vaccine strategies do not uniformly generate these antibodies. Our results indicate that stable expression of anti-HIV-1 antibody fragments is possible using a common *Lactobacillus* in the vaginal microbiota as a recombinant live biotherapeutic. m36.4 was used as a prototype antibody fragment, but other newly discovered broadly neutralizing antibodies might also be candidates to test in this approach.
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